Truist Securities Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Srikripa Devarakonda initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $50.
Truist Securities analyst Srikripa Devarakonda initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $50.